ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,386,565 | -44.7% | 826,095 | -0.8% | 0.01% | -43.8% |
| Q2 2023 | $7,934,106 | +48.3% | 832,540 | +71.2% | 0.02% | +33.3% |
| Q1 2023 | $5,348,640 | -25.4% | 486,240 | +0.3% | 0.01% | -25.0% |
| Q4 2022 | $7,171,370 | -23.3% | 484,552 | -1.0% | 0.02% | -30.4% |
| Q3 2022 | $9,352,000 | +15.5% | 489,345 | +28.8% | 0.02% | +21.1% |
| Q2 2022 | $8,095,000 | -15.2% | 379,895 | -23.3% | 0.02% | 0.0% |
| Q1 2022 | $9,544,000 | +9.7% | 495,450 | +18.1% | 0.02% | +11.8% |
| Q4 2021 | $8,704,000 | -6.6% | 419,674 | +7.6% | 0.02% | -10.5% |
| Q3 2021 | $9,316,000 | -14.1% | 389,938 | -1.8% | 0.02% | -13.6% |
| Q2 2021 | $10,840,000 | +118.8% | 397,216 | +132.0% | 0.02% | +100.0% |
| Q1 2021 | $4,954,000 | +356.2% | 171,203 | +343.5% | 0.01% | +450.0% |
| Q4 2020 | $1,086,000 | +69.4% | 38,604 | +76.5% | 0.00% | 0.0% |
| Q3 2020 | $641,000 | +182.4% | 21,876 | +191.7% | 0.00% | +100.0% |
| Q2 2020 | $227,000 | +1.3% | 7,500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $224,000 | – | 7,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |